Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Prescribing Guidelines: Public-Private Partnership Is Tackling Scope, Consequences

Executive Summary

US Action Collaborative plans to align guidelines for acute and chronic pain indications; panelist at public meeting questions whether focus should be on pain management rather than opioids.

You may also be interested in...



Califf Says Opioid Labeling Changes, Withdrawals Still Possible

The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.

US FDA Wants Opioid Prescribing Guidelines To Be Highly Specific, But It May Have To Compromise

National Academies of Sciences, Engineering, and Medicine committee meeting suggest it is difficult to write condition-specific guidelines for opioid prescribing in the primary care setting.

Updated: ImprimisRx's Approval And Superiority Claims For Compounded Drug Draw FDA Warning

The company known for compounding versions of Martin Shkreli’s Daraprim and Allergan’s Restasis is hit with a warning letter for promotions in professional periodicals about its compounded eye drop.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS125235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel